➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Boehringer Ingelheim
AstraZeneca
Medtronic
Dow

Last Updated: February 27, 2021

DrugPatentWatch Database Preview

Insulin lispro recombinant - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for insulin lispro recombinant

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Institut de Recherches Cliniques de MontrealPhase 2
Rigshospitalet, DenmarkPhase 4
Beta Bionics, Inc.Phase 2/Phase 3

See all insulin lispro recombinant clinical trials

Recent Litigation for insulin lispro recombinant

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
SANOFI-AVENTIS U.S. LLC v. MERCK SHARP & DOHME CORP.2017-08-08

See all insulin lispro recombinant litigation

Patent Text Search: US Patents for insulin lispro recombinant

These patents were identified by searching patent claims

Supplementary Protection Certificates for insulin lispro recombinant

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0023 France   Start Trial PRODUCT NAME: INSULIN GLARGINE; NAT. REGISTRATION NO/DATE: EU/0/00/134/001 20000609; FIRST REGISTRATION: EU/1/00/134/001 20000609
213 Luxembourg   Start Trial PRODUCT NAME: INSULINE DEGLUDEC SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/12/807/001-4-5-7-8-9-12-13-15 TRESIBA 20130123
13C/035 Belgium   Start Trial PRODUCT NAME: TRESIBA-INSULINE DEGLUDEC; AUTHORISATION NUMBER AND DATE: EU/1/12/807/001 20130121
C/GB05/024 United Kingdom   Start Trial PRODUCT NAME: INSULIN GLULISINE OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF; REGISTERED: UK EU/1/04/285/001 20040929; UK EU/1/04/285/002 20040929; UK EU/1/04/285/003 20040929; UK EU/1/04/285/004 20040929; UK EU/1/04/285/005 20040929; UK EU/1/04/285/006 20040929; UK EU/1/04/285/007 20040929; UK EU/1/04/285/008 20040929; UK EU/1/04/285/009 20040929; UK EU/1/04/285/010 20040929; UK EU/1/04/285/011 20040929; UK EU/1/04/285/012 20040929; UK EU/1/04/285/013 20040929; UK EU/1/04/285/014 20040929; UK EU/1/04/285/015 20040929; UK EU/1/04/285/016 20040929; UK EU/1/04/285/017 20040929; UK EU/1/04/285/018 20040929; UK EU/1/04/285/019 20040929; UK EU/1/04/285/020 20040929
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Dow
Boehringer Ingelheim
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.